VOYAGER THERAP. DL -,001 WKN: A143XJ ISIN: US92915B1061 Kürzel: VT6 Forum: Aktien Thema: Hauptdiskussion

Niemand hier in diesem Forum?

Doch.. Hab auch gekauft

Diro

HC Wainwright & Co. has updated their rating for Voyager Therapeutics ( $VYGR ) to Buy with a price target of 30.

To this end, Olson rates VYGR an Outperform (i.e., Buy), and his $18 price target implies room for a stunning 556% upside potential in the next 12 months. (To watch Olson’s track record, click here) Olson’s view is highly bullish, to be sure, but so is the general Street take here. VYGR shares have a Strong Buy consensus rating, based on 10 unanimously positive recommendations. The average price target stands at $15, pointing to potential upside of 447% from current levels. (See VYGR stock forecast)

HC Wainwright & Co. has adjusted their stance on Voyager Therapeutics ( $VYGR ), setting the rating to Buy with a target price of 30.

Wedbush upgraded Voyager Therapeutics () to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the name. The firm added the company’s tau antibody for Alzheimer’s disease program and the AAV-mediated siRNA program for amyotrophic lateral sclerosis caused by mutations in the SOD1 gene into its valuation. Voyager’s clinical and preclinical data that became available recently should allow for improved visibility into potential clinical outcomes for both programs, the analyst tells investors in a research note. With the pipeline moving forward closer to clinical entries and data readouts, and the shares trading near 52-week low, Wedbush believes Voyager represents an attractive investment opportunity “for investors with patience that are willing to tolerate the high risks associated with early stage clinical programs for neurodegenerative disorders.”

Gerade wieder nachgekauft

Niemand hier investiert? Keiner schreibt was…?

Warum der Anstieg

👀

Ja, i know🙄 danke dir!

🤷‍♀️

Dankeschön, danach kann’s ordentlich hochgehen?